Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
HIV infection Clinical criteria: Treatment Phase: Initial Patient must be antiretroviral treatment naive, AND The treatment must be in combination with other antiretroviral agents.
Chronic hepatitis B infection Clinical criteria: Patient must have cirrhosis, AND Patient must be nucleoside analogue naive, AND Patient must have detectable HBV DNA, AND The treatment must be the sole PBS-subsidised therapy for this condition. Patients with Child's class B or C cirrhosis (ascites, variceal bleeding, encephalopathy, albumin less than 30 g per L, bilirubin greater than 30 micromoles per L) should have their treatment discussed with a transplant unit prior to initiating therapy.
“Tenofovir disoproxil fumarate is a salt of an oral prodrug of tenofovir, a nucleoside monophosphate (nucleotide) analogue and obligate chain terminator with activity against HIV reverse transcriptase and HBV polymerase.”
“Tenofovir diphosphate has an intracellular half-life of 10 hours in activated and 50 hours in resting peripheral blood mononuclear cells (PBMCs).”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“In vitro studies have determined that neither tenofovir disoproxil fumarate nor tenofovir are substrates for the CYP450 enzymes. Moreover, at concentrations substantially higher (~ 300-fold) than those observed in vivo, tenofovir did not inhibit in vitro drug metabolism mediated by any of the major human CYP450 isoforms involved in drug biotransformation (CYP3A4, CYP2D6, CYP2C9, CYP2E1 or CYP1A1/2).”